Two important #COVID19 treatment studies were released this week. One, from @Merck got a lot of attn and soared on the stock markets. The other, with better results, from @Regeneron got little notice.
Key point with both: Best results come from treatment before symptoms.
3 MORE
Key point with both: Best results come from treatment before symptoms.
3 MORE
2/ @Merck press release: Gave molnupiravir to 385 people w/#COVID19 & placebo to 377.
After 29 days, 7.3% of molnupiravir group were either hospitalized or died, vs 14.1% of placebo-treated. So, says Merck, the drug cut the risk of severe COVID by 50%.
s2.q4cdn.com/584635680/file…
After 29 days, 7.3% of molnupiravir group were either hospitalized or died, vs 14.1% of placebo-treated. So, says Merck, the drug cut the risk of severe COVID by 50%.
s2.q4cdn.com/584635680/file…
3/ @Regeneron made combo monoclonal antibody treatment, REGEN-COV & pub'ed data in @NEJM .
28 days post-treatment, 1.3% of 1,355 treated patients were hospitalized or died, vs 4.6% of 728 placebo recipients.
So, REGEN-COVID cut acute disease risk by 71%.
cidrap.umn.edu/news-perspecti…
28 days post-treatment, 1.3% of 1,355 treated patients were hospitalized or died, vs 4.6% of 728 placebo recipients.
So, REGEN-COVID cut acute disease risk by 71%.
cidrap.umn.edu/news-perspecti…
4/ The @Merck drug is a pill. The @Regeneron is an infusion. Pills are easier to take, so the 50% risk reduction drew more enthusiasm on Wall St than the 71% with infusion.
But again, both are best given like #tamiflu for #flu -- before the person is sick.
Game shifts to testing.
But again, both are best given like #tamiflu for #flu -- before the person is sick.
Game shifts to testing.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
